Melanoma

Melanoma

Melanoma Molecular Biomarkers

About 44–70% of melanoma cases harbour a BRAF mutation. In cutaneous melanoma, the BRAF gene is mutated in ~60% of cases and p.V600E (c.1799T>A) accounts for more than 90% of BRAF mutations. This leads to constitutive activation of the MAPK pathway and increased cell proliferation, metastasis, and survival mechanisms. BRAF is also an important prognostic and treatment decision genetic biomarker in other cancer types1.

The current standard for determining eligibility of patients with metastatic melanoma for BRAF-targeted therapy is tissue-based testing of BRAF mutations. Targeted therapy with anti-BRAF inhibitors (BRAFi) remains the first-line treatment for melanoma tumours that harbour a BRAF mutation, particularly in Australia2.

Other oncogenic driver mutations have been identified in melanomas for which targeted therapies have demonstrated clinical activity. Detection of cKIT mutations may guide the selection of KIT TKIs (imatinib and sunitinib) for the melanoma treatment3. It has been shown that melanoma patients with cKIT mutations treated with imatinib may have a better outcome compared to BRAF melanoma patients treated with BRAF inhibitors4.

Another important oncogene, neuroblastoma RAS (NRAS) oncogene mutations have been more frequently detected in melanoma (13–25%) and in thyroid cancers (~6%) where they have been suggested to increase sensitivity to the mitogen-activated protein kinase signalling inhibitor (MEKi)5.

  • Somatic Mutation: Solid Tissue Molecular Profiling in Melanoma

    Somatic Mutation Brochure arrow icon   Somatic Mutation Request Form arrow icon

    Melanoma Solid Tissue Gene Panel

    Targeted therapy with Anti-BRAF (vemurafenib or dabrafenib) remains the first-line treatment for melanoma tumours which harbour a BRAF mutation, particularly in Australia1. In cutaneous melanoma, the BRAF gene is mutated in ~60% of cases and p.V600E (c.1799TA) accounts for more than 90% of BRAF mutations2. Detection of cKIT mutations may guide the selection of KIT TKIs (imatinib and sunitinib) for melanoma treatment3,4 and may lead to better outcomes compared to BRAF melanoma patients treated with BRAF inhibitors4.

    Genes sequenced in this panel include:

    Scroll indicator
    NRASBRAFcKIT
    Scroll indicator

    How to Order Somatic Mutation Melanoma Gene Panel

    When to Order:

    • At diagnosis or on therapy for treatment selection.

    Request Form Instructions:

    • Fill out our Somatic Mutation testing request form and tick the Somatic Mutation test panel required.

    Specimen Details:

    • Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue.

    Test Cost:

    • Medicare rebate available if criteria is met. If criteria is not met there is an out-of-pocket fee of $230.

    Turnaround Time:

    • 5-7 business days from the sample receipt date.

    Notes:

    • A negative result does not rule out the presence of a mutation that may be present but below the limits of detection for this assay (<5%).

    References
    1. Spagnolo F et al., (2015) Onco Targets Ther 8:157-168.
    2. Brose MS et al., (2002)     Cancer Res 62(23):6997–7000.
    3. Minor DR et al., (2012)     Clin Cancer Res 18:1457-63.
    4. Daniels M et al., (2011)     Cancer Lett 312:43-54.

  • Aspect ctDNA Liquid Biopsy in Melanoma

    Aspect Liquid Biopsy Doctor Brochure arrow icon Aspect Liquid Biopsy Request Form arrow icon

    Unfortunately, most melanoma patients receiving BRAFi therapy inevitably develop resistance to targeted therapy within six to 12 months. BRAF V600E mutations are associated with resistance to the tyrosine kinase inhibitors Cetuximab or Panitumumab.

    As patients are rarely re-biopsied, detection in blood might be advantageous by enabling a comprehensive assessment of tumour mutational status in real time and thereby representing a non-invasive biomarker for monitoring BRAF therapy.

    Haselmann et al. supported the routine use of ctDNA analysis to establish tumour genotype at diagnosis when treatment with targeted therapies is considered 1. Beyond the determination of baseline mutational status, the minimally invasive nature of ctDNA sample acquisition enables routine monitoring of response and resistance to targeted therapy2,3,4. This is of particular importance for melanoma patients because of the lack of clinically useful biomarkers.

    Furthermore, ctDNA can potentially be used as an immunotherapy predictive marker. Gray et al. and Lee et al. showed that baseline ctDNA levels predict response to immunotherapy, PD-1 inhibitor, in melanoma patients, and that low basal ctDNA levels were significantly associated with long-term clinical benefit 5,6.

    Melanoma ctDNA Gene Panel

    The Aspect Liquid Biopsy melanoma ctDNA gene panel can detect DNA alterations specific to melanoma as detailed below.

    Gene panel includes:

    • NRAS: 40 mutations across exon 2, 3 and 4
    • BRAF: 5 mutations across exon 11 and 15

    How to Order Aspect Liquid Biopsy

    When to Order:

    • For Lung Cancer & Melanoma: At diagnosis or on therapy for treatment selection.

    • For Colorectal Cancer: At diagnosis for treatment selection.

    Request Form Instructions:

    • Health practitioners can order Aspect Liquid Biopsy for cancer patients using the Aspect Liquid Biopsy form.

    • Patients can visit any of our convenient locations for their blood test. For locations, please visit our Locations page.

    Specimens Required:

    • This test requires TWO 10ml blood samples (special tubes).

    Test Cost:

    • No Medicare rebate available. An out-of-pocket fee of $550 applies.

    Turnaround Time:

    • 5–7 business days from the sample receipt date.

    Notes:

    • A negative result does not rule out the presence of a mutation that may be present but below the limits of detection for this assay (<2%).

    References:
    1. Haselmann V et al., (2018) Clinical Chemistry 64 (5):830–842.
    2. Spagnolo F et al., (2015) Onco Targets Ther 8:157–168.
    3. Garcia-Murillas I et al., (2015) Sci Transl Med 7 (302):302ra133–302ra133.
    4. Bettegowda C et al., (2014) Sci Transl Med 6:224ra24.
    5. Gray E et al., (2015) Oncotarget 6 (39):42008–42018.
    6. Lee J et al., (2017), Ann Oncol.

References

  1. Brose MS et al., (2002) Cancer Res 62(23):6997–7000.
  2. Spagnolo F et al., (2015) Onco Targets Ther 8:157–168.
  3. Minor DR et al., (2012) Clin Cancer Res 18:1457–1463.
  4. Daniels M et al., (2011) Cancer Lett 312:43–54.
  5. Fedorenko IV et al., (2017) Oncogene. 32:3009–3018.

About the Author

Associate Professor Mirette Saad

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD
Location: Clayton (VIC)
Speciality: Chemical Pathology
Areas of Interest:
  • antenatal screening
  • cancer genetics
  • clinical research and medical teaching
  • endocrine
  • fertility testing
  • molecular genetics
  • nipt
  • precision medicine
About

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from overseas. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for NIPT, antenatal screening, personalised drug therapy and cancer.